Elizabeth Halvorsen
Vice President - Translational Biology Seres Therapeutics
Elizabeth Halvorsen, PhD, is Vice President of Translational Biology at Seres Therapeutics, where she leads translational research strategies supporting the development of microbiome therapeutics. With more than a decade of experience spanning drug discovery through early clinical development, her expertise includes translational science, biomarker strategy, and immunology, with a focus on inflammatory and infectious diseases. Dr. Halvorsen has led cross-functional teams across preclinical and clinical programs, contributing to regulatory strategy, external scientific collaborations, and the advancement of innovative therapeutics from discovery toward the clinic.
Seminars
Tuesday 10th November 2026
Advancing Microbiome Therapeutics Through Deep Clinical Datasets & Reverse Translational Approaches to Drive LBP Development Success
1:30 pm
- Presenting recent Seres clinical trial insights demonstrating successful translation into previously inaccessible biology and disease targets unlocked by microbiome therapeutics
- Leveraging high-quality multi-omic clinical datasets and reverse translational approaches to develop novel LBP designs and microbiome-based biomarkers
- Applying clinical learnings to support early phase proof-of-concept success and build compelling evidence packages for potential collaborator engagement
